MCID: SMN007
MIFTS: 43

Seminoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Seminoma

MalaCards integrated aliases for Seminoma:

Name: Seminoma 12 74 54 43 15 71
Seminoma, Pure 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4440
MeSH 43 D018239
NCIt 49 C9309
SNOMED-CT 67 36741007 443675005
UMLS 71 C0036631

Summaries for Seminoma

Disease Ontology : 12 A germinoma that has material basis in cells that make sperm and eggs.

MalaCards based summary : Seminoma, also known as seminoma, pure, is related to testicular seminoma and extragonadal seminoma. An important gene associated with Seminoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cardiac Progenitor Differentiation and Thiamine metabolism. The drugs Granisetron and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include testis, lymph node and testes, and related phenotype is digestive/alimentary.

Wikipedia : 74 A seminoma is a germ cell tumor of the testicle or, more rarely, the mediastinum or other extra-gonadal... more...

Related Diseases for Seminoma

Diseases related to Seminoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 testicular seminoma 35.1 CGB3 AFP
2 extragonadal seminoma 34.6 KIT AFP
3 mediastinum seminoma 34.5 KIT ALPP AFP
4 testicular spermatocytic seminoma 34.4 MAGEA4 FGFR3
5 testicular germ cell tumor 34.1 KIT FGFR3 CGB3 ALPP ALPG AFP
6 spermatocytoma 33.6 SSX2 MAGEA4 KIT FGFR3 AFP
7 nonseminomatous germ cell tumor 33.3 CGB7 AFP
8 embryonal carcinoma 32.7 TNFRSF8 POU5F1 KIT IGF2 CGB3 ALPG
9 mixed germ cell cancer 32.5 TNFRSF8 KIT AFP
10 testicular cancer 32.5 SSX2 MAGEA4 DAZL CGB3 ALPP AFP
11 cryptorchidism, unilateral or bilateral 31.2 POU5F1 KIT DAZL ALPG AFP
12 teratoma 31.1 POU5F1 KIT FGFR3 ENO2 CGB7 CGB3
13 mixed germ cell tumor 31.1 KIT CGB3 AFP
14 endodermal sinus tumor 31.0 TNFRSF8 POU5F1 KIT CGB3 AFP
15 gonadal dysgenesis 30.9 POU5F1 KIT CGB3
16 gonadoblastoma 30.9 POU5F1 KIT CGB3 ALPP ALPG
17 central nervous system germinoma 30.9 POU5F1 ALPP
18 sertoli cell tumor 30.8 INHA ENO2 ALPP AFP
19 choriocarcinoma 30.8 INHA IGF2 CGB7 CGB3 ALPP ALPG
20 intermediate malignant teratoma 30.8 TNFRSF8 AFP
21 germinoma 30.8 POU5F1 PDPN KIT INHA CGB3 ALPP
22 sarcoma 30.7 SSX2 POU5F1 KIT FGFR3 ENO2
23 mature teratoma 30.7 TNFRSF8 POU5F1 KIT ENO2 AFP
24 leiomyosarcoma 30.7 KIT IGF2 ENO2
25 dysgerminoma of ovary 30.6 POU5F1 KIT AFP
26 dysgerminoma 30.6 POU5F1 KIT INHA ENO2 ALPP ALPG
27 cystic teratoma 30.6 KIT ENO2 AFP
28 brain germinoma 30.6 POU5F1 MAGEA4 KIT AFP
29 malignant teratoma 30.6 TNFRSF8 POU5F1 KIT ENO2 AFP
30 testicular disease 30.5 TNFRSF8 POU5F1 KIT AFP
31 hepatic tuberculosis 30.5 ALPP AFP
32 mediastinal cancer 30.4 TNFRSF8 KIT ENO2 AFP
33 chromosomal triplication 30.4 CGB7 CGB3 AFP
34 germ cell cancer 30.3 POU5F1 NLRP7 KIT IGF2 ENO2 ALPP
35 mast-cell sarcoma 30.3 TNFRSF8 KIT
36 complete androgen insensitivity syndrome 30.3 IGF2 ALPG
37 intratubular embryonal carcinoma 30.2 TNFRSF8 POU5F1 KIT AFP
38 gastrointestinal stromal tumor 30.1 KIT IGF2 FGFR3 ENO2
39 sarcoma, synovial 30.0 TNFRSF8 SSX2 KIT IGF2
40 hemangiopericytoma, malignant 29.9 SSX2 KIT IGF2 ENO2
41 peripheral t-cell lymphoma 29.8 TNFRSF8 TCL1A FGFR3
42 pineal gland cancer 29.5 ENO2 AFP
43 testis seminoma 12.5
44 tubular variant testicular seminoma 12.2
45 cribriform variant testicular seminoma 12.2
46 pseudoglandular variant testicular seminoma 12.2
47 germ cells tumors 10.7
48 gallbladder leiomyosarcoma 10.6 KIT AFP
49 liver leiomyoma 10.6 KIT AFP
50 sacrococcygeal teratoma 10.6 CGB7 AFP

Graphical network of the top 20 diseases related to Seminoma:



Diseases related to Seminoma

Symptoms & Phenotypes for Seminoma

MGI Mouse Phenotypes related to Seminoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 FGFR3 IGF2 INHA KIT MMP16 PDPN

Drugs & Therapeutics for Seminoma

Drugs for Seminoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Captopril Approved Phase 3 62571-86-2 44093
4
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
5
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
6
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
7
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
8
Ribavirin Approved Phase 3 36791-04-5 37542
9
Palivizumab Approved, Investigational Phase 3 188039-54-5
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
11
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Etoposide Approved Phase 3 33419-42-0 36462
14
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
15
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
16
Lenograstim Approved, Investigational Phase 3 135968-09-1
17
Mesna Approved, Investigational Phase 3 3375-50-6 598
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
20
Promethazine Approved, Investigational Phase 3 60-87-7 4927
21
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
22
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
23
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
24
Ifosfamide Approved Phase 3 3778-73-2 3690
25
Vinblastine Approved Phase 3 865-21-4 241903 13342
26 Gastrointestinal Agents Phase 3
27 Antiemetics Phase 3
28 Neurotransmitter Agents Phase 3
29 Anti-Infective Agents Phase 3
30 Immunosuppressive Agents Phase 3
31 Antiviral Agents Phase 3
32 Antimetabolites Phase 3
33 Liver Extracts Phase 3
34 Antirheumatic Agents Phase 3
35 Antihypertensive Agents Phase 3
36 Angiotensin-Converting Enzyme Inhibitors Phase 3
37 HIV Protease Inhibitors Phase 3
38
protease inhibitors Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3
40 Hormone Antagonists Phase 3
41 Hormones Phase 3
42
Hydroxyitraconazole Phase 3
43 Antifungal Agents Phase 3
44 Cytochrome P-450 CYP3A Inhibitors Phase 3
45 glucocorticoids Phase 3
46 Cola Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 Amebicides Phase 3
50 Antiparasitic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
2 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
3 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
4 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
5 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
6 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
7 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
8 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
9 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
14 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
15 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
16 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
17 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
18 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
19 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
20 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
21 Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors Completed NCT01055067 Phase 2 Tivantinib (ARQ 197)
22 A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT Completed NCT02272816 Phase 2 Carboplatin AUC-10
23 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
24 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
25 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
26 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
27 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
28 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
29 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
30 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
31 Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients Completed NCT00423852 Phase 1, Phase 2 carboplatin;ifosfamide;paclitaxel
32 A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors Completed NCT00957905 Phase 2 Alvocidib Hydrochloride;Fluorouracil;Leucovorin Calcium;Oxaliplatin
33 PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER Completed NCT00002903 Phase 2 docetaxel
34 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
35 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
36 Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma Recruiting NCT01887340 Phase 2 Carboplatin;Etoposide;Cisplatin
37 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts Recruiting NCT03937843 Phase 2 Carboplatin;Cisplatin;Etoposide
38 A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors Recruiting NCT03158064 Phase 2 Durvalumab;Tremelimumab
39 A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Recruiting NCT02317393 Phase 2
40 Phase II Single-arm Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST) Recruiting NCT02797626 Phase 2
41 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Recruiting NCT00432094 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel;thiotepa;Mesna
42 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
43 Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma Active, not recruiting NCT01593241 Phase 2 Carboplatin
44 A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma Terminated NCT00042952 Phase 2 imatinib mesylate
45 Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors Terminated NCT01808534 Phase 2 palifosfamide
46 Phase II Multi-institutional Proof of Concept Single-arm Trial of Nivolumab in the Treatment of Patients With Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Withdrawn NCT03726281 Phase 2 Nivolumab
47 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
48 A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors Completed NCT00313599 Phase 1 lapatinib;paclitaxel
49 CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
50 Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours: Potential Risks and Consequences for the Conceptus Unknown status NCT03262207

Search NIH Clinical Center for Seminoma

Cochrane evidence based reviews: seminoma

Genetic Tests for Seminoma

Anatomical Context for Seminoma

MalaCards organs/tissues related to Seminoma:

40
Testis, Lymph Node, Testes, Bone, Prostate, Ovary, Lung

Publications for Seminoma

Articles related to Seminoma:

(show top 50) (show all 5281)
# Title Authors PMID Year
1
TCL1 protein expression in testicular germ cell tumors. 61 54
20395523 2010
2
SCF and c-kit expression profiles in male individuals with normal and impaired spermatogenesis. 54 61
20384797 2010
3
Immunohistochemical expression of the KIT protein (CD117) in normal and neoplastic canine testes. 54 61
19683721 2010
4
Expression of embryonic stem cell markers in cultured JKT-1, a cell line derived from a human seminoma. 61 54
19226408 2010
5
Analysis of activin/TGFB-signaling modulators within the normal and dysfunctional adult human testis reveals evidence of altered signaling capacity in a subset of seminomas. 61 54
19661148 2009
6
The utility of microscopic findings and immunohistochemistry in the classification of necrotic testicular tumors: a study of 11 cases. 54 61
19461507 2009
7
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein. 54 61
19493258 2009
8
Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia. 61 54
19493328 2009
9
Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes. 54 61
19245437 2009
10
Absence of gene mutations in KIT-positive thymic epithelial tumors. 54 61
18486988 2008
11
[Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas]. 61 54
18971108 2008
12
Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. 61 54
18787014 2008
13
Expression of connexin 43 in normal canine testes and canine testicular tumors. 54 61
18542985 2008
14
[Case report of malignant sertoli cell tumor]. 54 61
18697473 2008
15
Abnormal hCG levels in a patient with treated stage I seminoma: a diagnostic dilemma. 61 54
18578862 2008
16
Further characterization of the first seminoma cell line TCam-2. 54 61
18050305 2008
17
[Management of testicular seminoma with elevation of alpha fetoprotein. A case report]. 61 54
18472076 2008
18
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. 54 61
18223323 2008
19
Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. 54 61
18045648 2008
20
Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. 61 54
17943970 2008
21
c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. 54 61
17768701 2007
22
Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. 61 54
17951198 2007
23
Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. 54 61
17682839 2007
24
Histologically pure stage I seminoma with an elevated beta-hCG of 4497 IU/l. 54 61
18068467 2007
25
Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. 61 54
17976614 2007
26
KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. 54 61
17573850 2007
27
Classical and spermatocytic seminoma in the dog: histochemical and immunohistochemical findings. 61 54
17629966 2007
28
Kit expression in male germ cell tumors. 61 54
17595797 2007
29
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. 54 61
16960727 2007
30
OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. 61 54
17117392 2007
31
[CT diagnosis and pathological findings of testicular lesion]. 54 61
17259159 2007
32
[A case of seminoma with a low level positive of serum hCG (human chorionic gonadotropin) beta considered as false positive hCGbeta]. 61 54
17025215 2006
33
Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. 61 54
16741525 2006
34
Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas. 61 54
16918976 2006
35
Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. 54 61
16736189 2006
36
Transition from preinvasive carcinoma in situ to seminoma is accompanied by a reduction of connexin 43 expression in Sertoli cells and germ cells. 61 54
16820096 2006
37
Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. 61 54
16718353 2006
38
Retroperitoneal seminoma in limited biopsies: morphologic criteria and immunohistochemical findings in 30 cases. 61 54
16723857 2006
39
Rosai-Dorfman disease of the testis: an unusual entity that mimics testicular malignancy. 54 61
16505287 2006
40
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. 54 61
16397263 2006
41
Targeting the active site of the placental isozyme of alkaline phosphatase by phage-displayed scFv antibodies selected by a specific uncompetitive inhibitor. 54 61
16372914 2005
42
KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. 61 54
16188233 2005
43
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. 61 54
16228988 2005
44
Immunohistochemical expression of calretinin in canine testicular tumours and normal canine testicular tissue. 54 61
15924929 2005
45
Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. 61 54
16166280 2005
46
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 61 54
16082245 2005
47
CD30 (Ki-1) molecule expression in human embryonal epithelial cells of the basal layer of the developing epidermis and epidermal buds and its potential significance for embryogenesis. 61 54
16200333 2005
48
Identification of two molecular groups of seminomas by using expression and tissue microarrays. 61 54
16115909 2005
49
Estrogen-induced growth inhibition of human seminoma cells expressing estrogen receptor beta and aromatase. 54 61
16087732 2005
50
No predictive value of beta-hCG in patients with stage I seminoma--results of a long-term follow-up study after adjuvant radiotherapy. 61 54
16033057 2005

Variations for Seminoma

Copy number variations for Seminoma from CNVD:

7 (show all 13)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 55928 11 56400000 134452384 Loss Seminomas
2 61576 12 1 56300000 Gain Seminomas
3 119165 18 1 15400000 Loss Seminomas
4 120979 18 35500000 76117153 Loss Seminomas
5 138723 2 169500000 182700000 Gain Seminomas
6 146936 2 56300000 182700000 Loss Seminomas
7 157118 21 12300000 46944323 Gain Seminomas
8 160299 22 11800000 49691432 Loss Seminomas
9 217037 7 1 158821424 Gain Seminomas
10 237233 8 2200000 146274826 Gain Seminomas
11 257126 X 1 24900000 Gain Seminomas
12 262546 X 37500000 154913754 Gain Seminomas
13 262571 X 37500000 47300000 Gain Seminomas

Expression for Seminoma

Search GEO for disease gene expression data for Seminoma.

Pathways for Seminoma

Pathways related to Seminoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.52 POU5F1 KIT IGF2
2 10.16 ALPP ALPG

GO Terms for Seminoma

Cellular components related to Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MMP16 KIT INHA IGF2 ENO2 CGB7

Biological processes related to Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 9.5 TCL1A POU5F1 PDPN KIT IGF2 FGFR3
2 cell-cell signaling GO:0007267 9.46 INHA FGFR3 CGB7 CGB3
3 chondrocyte proliferation GO:0035988 9.26 MMP16 FGFR3
4 skeletal system development GO:0001501 8.92 MMP16 INHA IGF2 FGFR3

Molecular functions related to Seminoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alkaline phosphatase activity GO:0004035 8.96 ALPP ALPG
2 hormone activity GO:0005179 8.92 INHA IGF2 CGB7 CGB3

Sources for Seminoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....